EGFR and non-small cell lung carcinoma: For patients with WT EGFR tumors that account for a majority of NSCLC worldwide, the options were limited to cytotoxic chemotherapy in first-line setting, which being modest in extending survival; and in second- or higher line setting, the recommendation was less clear [13].